HMGCR and cholelithiasis: Making dietary changes, such as reducing the intake of fatty foods, can sometimes help prevent the progression of asymptomatic gallstones into symptomatic ones.[47–49] In a drug-target MR analysis, HMGCR inhibition contributed to reducing the cholelithiasis risk.[8] Moreover, through the activation of PPARα-mediated CYP7A1 expression and the facilitation of the conversion of cholesterol into BAs, PCSK9 inhibition has both preventative and therapeutic effects on cholesterol gallstones.[50] Our study has some potential limitations.